missing translation for 'onlineSavingsMsg'
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. 18174302

ATRIP Antibody (OTI5E7), DyLight 680, Novus Biologicals™

Mouse Monoclonal Antibody

Brand:  Novus Biologicals NBP2-72271FR

Product Code. 18174302

  • € 751.00 / 0.10mL

Please to purchase this item. Need a web account? Register with us today!

This item is not returnable. View return policy

Description

Description

ATRIP Monoclonal specifically detects ATRIP in Human, Canine samples. It is validated for Western Blot, Flow Cytometry, Immunohistochemistry, Immunocytochemistry/Immunofluorescence.
TRUSTED_SUSTAINABILITY
Specifications

Specifications

ATRIP
Monoclonal
DyLight 680
PBS with 0.05% Sodium Azide
ATRIP
Recombinant protein fragment corresponding to amino acids 42-309 of human ATRIP (NP_569055) produced in E.coli.
0.1 mL
Primary
Human, Canine
IgG2a
Western Blot, Flow Cytometry, Immunohistochemistry, Immunocytochemistry, Immunofluorescence
OTI5E7
Western Blot, Flow Cytometry, Immunohistochemistry, Immunocytochemistry/Immunofluorescence
AGS1, ATM and Rad3-related-interacting protein, ATR interacting protein, ATR-interacting protein, DKFZp762J2115, FLJ12343, MGC20625, MGC21482, MGC26740
Mouse
Affinity Purified
Cancer, Checkpoint signaling, DNA Double Strand Break Repair, DNA Repair
84126.0
Store at 4°C in the dark.
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.